These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 21912195)

  • 1. Clinical and pathological features of breast cancer associated with the pathological complete response to anthracycline-based neoadjuvant chemotherapy.
    Keskin S; Muslumanoglu M; Saip P; Karanlık H; Guveli M; Pehlivan E; Aydoğan F; Eralp Y; Aydıner A; Yavuz E; Ozmen V; Igci A; Topuz E
    Oncology; 2011; 81(1):30-8. PubMed ID: 21912195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of residual breast disease and axillary node involvement for patients who had primary induction chemotherapy for advanced breast cancer.
    Escobar PF; Patrick RJ; Rybicki LA; Hicks D; Weng DE; Crowe JP
    Ann Surg Oncol; 2006 Jun; 13(6):783-7. PubMed ID: 16604475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
    Shimizu C; Masuda N; Yoshimura K; Tsuda H; Mano M; Ando M; Tamura K; Fujiwara Y
    Jpn J Clin Oncol; 2009 Aug; 39(8):484-90. PubMed ID: 19477897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation.
    Gimbergues P; Abrial C; Durando X; Le Bouedec G; Cachin F; Penault-Llorca F; Mouret-Reynier MA; Kwiatkowski F; Maublant J; Tchirkov A; Dauplat J
    Ann Surg Oncol; 2008 May; 15(5):1316-21. PubMed ID: 18311507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
    Pierga JY; Mouret E; Diéras V; Laurence V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Vincent-Salomon A; Scholl S; Extra JM; Asselain B; Pouillart P
    Br J Cancer; 2000 Dec; 83(11):1480-7. PubMed ID: 11076657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy analysis of THP-containing regimens as neoadjuvant and adjuvant chemotherapy for primary breast cancer].
    Wang LZ; Ouyang T; Wang TF; Xie YT; Fan ZQ; Fan T; Lin BY; Li JF
    Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):143-6. PubMed ID: 22780935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer?
    Uematsu T; Kasami M; Watanabe J; Takahashi K; Yamasaki S; Tanaka K; Tadokoro Y; Ogiya A
    Breast Cancer; 2011 Oct; 18(4):309-13. PubMed ID: 20574730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SerpinB3, a new prognostic tool in breast cancer patients treated with neoadjuvant chemotherapy.
    Collie-Duguid ES; Sweeney K; Stewart KN; Miller ID; Smyth E; Heys SD
    Breast Cancer Res Treat; 2012 Apr; 132(3):807-18. PubMed ID: 21695460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.
    Le Tourneau C; Dettwiler S; Beuzeboc P; Alran S; Laurence V; Pierga JY; Fréneaux P; Sigal-Zafrani B; Diéras V; Vincent-Salomon A
    Am J Clin Oncol; 2012 Jun; 35(3):242-6. PubMed ID: 21358298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
    Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin-docetaxel neoadjuvant chemotherapy: a cohort study.
    Kai K; Arima N; Miyayama H; Yamamoto Y; Iwase H; Nishimura R
    Breast Cancer; 2009; 16(1):42-8. PubMed ID: 18504642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome.
    Mazouni C; Peintinger F; Wan-Kau S; Andre F; Gonzalez-Angulo AM; Symmans WF; Meric-Bernstam F; Valero V; Hortobagyi GN; Pusztai L
    J Clin Oncol; 2007 Jul; 25(19):2650-5. PubMed ID: 17602071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast.
    Botti C; Vici P; Lopez M; Scinto AF; Cognetti F; Cavaliere R
    J Am Coll Surg; 1995 Sep; 181(3):202-8. PubMed ID: 7670678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients.
    Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1062-73. PubMed ID: 15234040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
    Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of lymph node metastasis in the systemic dissemination of breast cancer.
    Nathanson SD; Kwon D; Kapke A; Alford SH; Chitale D
    Ann Surg Oncol; 2009 Dec; 16(12):3396-405. PubMed ID: 19657697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic tumor response of invasive lobular carcinoma to neo-adjuvant chemotherapy.
    Joh JE; Esposito NN; Kiluk JV; Laronga C; Khakpour N; Soliman H; Catherine Lee M
    Breast J; 2012; 18(6):569-74. PubMed ID: 23034096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
    McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
    Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.